Contezolid acefosamil

康泰唑胺磷酸盐

Report date: 2025/06/26 20:00:07
NMEQIDP

Base Information

Drug NameContezolid acefosamil
Drug Alias NameT79C086548 (UNII code)MRX-4-MicuRxMRX-IVMRX-4
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Oxazolidinone antibiotics
Mechanisms of Action50S ribosomal subunit inhibitorsProtein biosynthesis inhibitors
Targets50S ribosomal subunit
Therapy Area/IndicationsHospital-acquired pneumoniaComplicated Skin and Soft Tissue InfectionsEnterococcus faecium infections +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesPoland +[9] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMicuRx Pharmaceutical Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesMicuRx Pharmaceutical IncShanghai MicuRx Pharmaceutical Co LtdMengke Medical Technology (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsHospital-acquired pneumoniaComplicated Skin and Soft Tissue InfectionsEnterococcus faecium infections +[8] 
Inactive IndicationsSkin Diseases, Bacterial

Other Information

ATC CodeJ01XX
Related LinksN/A